|
01/31/12 |
|
|
|
|
|
|
Biogen Idec Surpasses $5 Billion in 2011 Annual Revenue |
|
|
|
|
01/30/12 |
|
|
|
|
|
|
|
|
|
|
|
|
GSK joins new global partnership to help defeat ten
neglected tropical diseases by 2020
|
|
|
|
|
|
Novartis extends commitment to help achieve final
elimination of leprosy |
|
|
|
|
|
FDA approves Jentadueto™ (linagliptin/metformin
hydrochloride) tablets for the treatment of adult patients with type 2
diabetes |
|
|
|
|
01/27/12 |
|
|
|
|
|
|
|
|
|
|
|
01/26/12 |
Biogen
IdecASCEND
Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a
Treatment for Secondary-Progressive Multiple Sclerosis |
|
|
|
|
|
Amgen to Acquire Micromet
|
|
|
|
|
|
Amgen's Full Year 2011 Revenue Increased 4 Percent to
$15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent
to $5.33 |
|
|
|
|
01/25/12 |
MERCK:New
FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin)
Includes Results From the Study of Heart and Renal Protection (SHARP) in
Patients With Moderate to Severe Chronic Kidney Disease
|
|
|
|
|
01/24/12 |
Life Technologies Acquires UK-Based Matrix MicroScience;
Cuts Food Pathogen Testing Workflow and Cost Per Sample by 50 Percent
|
|
|
|
|
|
Gilead Initiates Phase 2 Clinical Trial Evaluating
GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV |
|
|
|
|
|
Elanco Animal Health Announces Lilly's Agreement to
Acquire ChemGen Corp.
|
|
|
|
|
|
|
|
|
|
|
01/23/12 |
Roche medicine Avastin receives EU approval for the
treatment of women with newly diagnosed, advanced ovarian cancer
|
|
|
|
|
|
Millenium:
FDA Approves Subcutaneous Administration of VELCADE® In
All Approved Indications |
|
|
|
|
01/20/12 |
|
|
|
|
|
|
|
|
|
|
|
01/19/12 |
|
|
|
|
|
|
Merck Resolves Vioxx® Litigation in Canada
|
|
|
|
|
01/18/12 |
Agilent Technologies Announces First Cash Dividend of 10
Cents per Share |
|
|
|
|
|
Myriad Genetics Acquires Exclusive Rights to RAD51C Gene
|
|
|
U.S. Food and Drug Administration Approves New
Formulations of Viread® for Use by Children Living With HIV |
|
|
|
|
01/17/12 |
Thermo Fisher Scientific Couples Chromatography and Mass
Spec Systems to Develop Method for Detecting Arsenic in Apple Juice |
|
|
|
|
|
Agilent Technologies Lists LC and Mass Spec Systems as
Class I Medical Devices with FDA |
|
|
|
|
|
|
|
|
|
|
01/16/12 |
Bruker Announces $1.3 Million Contract with ThyssenKrupp
Stainless USA for Elemental Analysis Equipment in new State-of-the-Art
Steel Melt Shop |
|
|
|
|
|
Agilent Technologies Replaces Signal-to-Noise Spec with
Instrument Detection Limit for Triple Quadrupole GC/MS |
|
|
|
|
01/13/12 |
Bristol-Myers Squibb Begins Tender Offer to Acquire
Inhibitex, Inc. |
|
|
|
|
|
Genentech Announces First Milestone Payment to
Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery
Lucentis |
|
|
|
|
01/12/12 |
Gilead Sciences Completes Tender Offer for All
Outstanding Shares of Pharmasset, Inc. |
|
|
|
|
01/11/12 |
GSK responds to the recent court ruling on the COMPAS
study in Mendoza, Argentina |
|
|
|
|
01/10/12 |
Life Technologies Introduces the Benchtop Ion Proton™
Sequencer; Designed to Decode a Human Genome in One Day for $1,000
|
|
|
|
|
01/09/12 |
Agilent Technologies Announces Launch of the World's
First Triple Quadrupole ICP-MS |
|
|
|
|
01/07/12 |
Caliper CEO Kevin Hrusovsky Presented Vision for
Revolutionizing Medicine |
|
|
|
|
01/06/12 |
Thermo Fisher Scientific Introduces Unity Lab Services |
|
|
|
|
|
FDA Approves Merck’s ISENTRESS® (raltegravir)
for Use in Children Ages Two Years and Older as Part of HIV-1
Combination Therapy |
|
|
|
|
01/04/12 |
Vermillion Sharpens Focus and Streamlines Operations in
2012 |
|
|
|
|
|
Biogen Idec and Isis Pharmaceuticals Announce Global
Collaboration for Antisense Program Targeting Spinal Muscular Atrophy |
|
|
|
|
12/14/11 |
Amgen Announces Final Results of Its Tender Offer
|
|
|
|
|
12/13/11 |
Millenium:
Presentations Highlight Results of Studies with MLN9708,
First Oral Proteasome Inhibitor in Early Stage Clinical Trials in
Multiple Myeloma |
|
|
|
|
|
Nordion Inc. Declares Quarterly Dividend |
|
|
|
|
|
Yale University Adopts Multiple Agilent Platforms for
Integrative Biology Research at New West Campus |
|
|
|
|
12/12/11 |
Merck Announces Results of ZOLINZA® (vorinostat)
Phase III and IIb Trials for Investigational Use for Multiple Myeloma at
American Society of Hematology Annual Meeting
|
|
|
|
|
12/08/11 |
Lilly:
Taking Sex Off Their To-Do List: Most Couples Prefer
Spontaneity in the Bedroom |
|
|
|
|
12/07/11 |
Genentech Announces Positive Results of Pivotal Phase III
Study with Pertuzumab in HER2-Positive Metastatic Breast Cancer |
|
|
|
|
|
Samsung and Biogen Idec Announce Joint Venture to
Develop, Manufacture and Market Biosimilars |
|
|
|
|
|
Agilent Technologies Instruments Chosen in Major Upgrade
of Virginia Tech's Chemistry Department |
|
|
|
|
12/05/11 |
Bayer:
Two year results of Phase III Studies with VEGF Trap-Eye
in Wet Age-related Macular Degeneration Show Sustained Improvement in
Visual Acuity |
|
|
|
|
12/02/11 |
BMS
Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for
Phase II Combination Study in Patients Chronically Infected with
Hepatitis C |
|
|
|
|
|
|
|
|
|
|
12/01/11 |
Bruker Announces Partnership with GRAST at Chungnam
National University in Korea to Develop Glycomics Reference Site |
|
|
|
|
11/30/11 |
Abbott Receives FDA Clearance for New Test to Detect
Vitamin D Levels |
|
|
|
|
11/29/11 |
Pfizer:
|
|
|
|
|
|
BMS:
FDA Accepts ELIQUIS® (apixaban) New Drug Application for
Review for the Prevention of Stroke and Systemic Embolism in Patients
with Atrial Fibrillation |
|
|
|
|
|
Genentech to Present Important New Data for HER2-Positive
Breast Cancer at 2011 San Antonio Breast Cancer Symposium |
|
|
|
|
|
Bruker Introduces Novel TERS-Ready AFM System |
|
|
|
|
11/28/11 |
|
|
|
|
|
|
BMS:
ONGLYZA® (saxagliptin) Approved for Use in Europe as
Combination Therapy With Insulin (With or Without Metformin) in Adults
With Type 2 Diabetes |
|
|
|
|
11/23/11 |
Agilent Technologies GC/MS and LC/MS Systems Receive International
Design Awards |
|
|
|
|
11/22/11 |
|
|
|
|
|
|
Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S.
Attorney's Office for the District of Massachusetts Related to Vioxx®
|
|
|
|
|
11/21/11 |
|
|
|
|
|
|
|
|
|
|
|
|
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion |
|
|
|
|
|
Abbott Introduces the First FDA-Approved Supplemental Blood Test for
Chagas Disease |
|
|
|
|
11/18/11 |
FDA Commissioner Announces Final Decision on Avastin for Metastatic
Breast Cancer |
|
|
|
|
|
U.S. FDA Approves EYLEA™ (aflibercept) Injection for the Treatment of
Wet Age-Related Macular Degeneration |
|
|
|
|
11/17/11 |
|
|
|
|
|
|
|
|
|
|
|
|
Bristol-Myers Squibb Foundation Awards $2.34 Million in Grants to Help
Prisoners with Mental Illness Return to Community |
|
|
|
|
|
|
|
|
|
|
|
Bayer scientific magazine:
Personalized medicine against cancer / Creating new active crop
protection ingredients with biotechnology |
|
|
|
|
11/16/11 |
FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with
Myelofibrosis |
|
|
|
|
|
|
|
|
|
|
11/15/11 |
NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination
with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian
Cancer |
|
|
|
|
11/11/11 |
Thermo Fisher Scientific to Buy Back its Common Stock |
|
|
|
|
11/09/11 |
Bruker Announces Four Ultra-High Field NMR Orders from
the Central European Institute of Technology (CEITEC) to Enable Advanced
Biological Research |
|
|
|
|
11/08/11 |
FDA Accepts Genentech's New Drug Application For
Vismodegib in Advanced Form of Skin Cancer |
|
|
|
|
|
Lilly and Amylin Mutually Agree to End Diabetes Alliance
and Transition Exenatide Responsibility to Amylin
|
|
|
|
|
11/03/11 |
BMS:FDA
Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or
Metastatic Head and Neck Cancer in Combination with Platinum-based
Chemotherapy with 5-Fluorouracil |
|
|
|
|
|
Vermillion Receives Notice of Allowance for 5th Biomarker
Patent Related to Peripheral Artery Disease |
|
|
|
|
10/28/11 |
|
|
|
|
|
10/24/11 |
DxTerity and Caliper Life Sciences Partner to Deliver
NEAT® Multiplex Assays on Caliper's LabChip® Dx Platform |
|
|
|
|
10/21/11 |
Biogen:
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced
Multiple Sclerosis (MS) Relapses and Disability Progression in Define
Phase 3 Clinical Trial |
|
|
|
|
10/20/11 |
Agilent Technologies and University of Technology,
Sydney, Open Joint Nuclear Magnet Resonance Facility |
|
|
|
|
|
Geron Presents Clinical Data Update from GRNOPC1 Spinal
Cord Injury Trial |
|
|
|
|
10/19/11 |
Bristol-Myers Squibb Announces Changes in Senior
Management Team |
|
|
|
|
|
Genentech: Phase II Study Showed Ocrelizumab Maintained
Significant Reduction in Disease Activity for Multiple Sclerosis
Patients for Almost Two Years |
|
|
|
|
10/18/11 |
|
|
|
|
|
10/17/11 |
|
|
|
|
|
10/14/11 |
Shimadzu Corporation and Shimane University Sign Joint
Research Agreement for Neonatal Mass Screening Using Tandem Mass
Spectrometry |
|
|
|
|
10/12/11 |
Ion Torrent Cancer Panel Finds Mutations in One Day
|
|
|
|
|
10/11/11 |
Agilent Technologies Introduces Its First Sub-2-Micron
UHPLC Column for Reversed-Phase Protein Characterization |
|
|
|
|
10/05/11 |
Gilead and Boehringer Ingelheim Sign License Agreement
for Novel HIV Non-Catalytic Integrase Inhibitors |
|
|
|
|
9/27/11 |
|
|
|
|
|
9/26/11 |
|
|
|
|
|
|
Lilly:
ALIMTA Receives Positive Opinion From CHMP as
Continuation Maintenance Therapy for Deadly Form of Lung Cancer
|
|
|
|
|
9/24/11 |
Genentech's Investigational Medicine T-DM1 Showed
Improvement in Progression-Free Survival Compared to Standard of Care in
HER2-Positive Metastatic Breast Cancer |
|
|
|
|
9/23/11 |
|
|
|
|
|
|
Roche’s Avastin receives positive opinion from European
authority for the treatment of women with newly diagnosed advanced
ovarian cancer |
|
|
|
|
9/19/11 |
Merck's ISENTRESS® (raltegravir) in
Combination Therapy Demonstrated Efficacy and Tolerability in an
Observational Trial in a Diverse Population of Adults with HIV-1
Regardless of Gender or Race |
|
|
|
|
|
Amgen:FDA
Approves New Indications for Prolia® (Denosumab) for the Treatment of
Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone
Ablation Therapy |
|
|
|
|
|
Amgen:
FDA Approves New Indications for Prolia® (Denosumab) for
the Treatment of Bone Loss in Patients With Prostate or Breast Cancer
Undergoing Hormone Ablation Therapy
|
|
|
|
|
9/16/11 |
Millennium Ranked In Top 10 Biotech / Biopharmaceutical
Companies For 4th Consecutive Year |
|
|
|
|
|
BMS:
ONGLYZA™ (saxagliptin) When Added to Insulin in Adults
with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels (HbA1c)
Over 52 Weeks in Investigational Study Extension |
|
|
|
|
9/13/11 |
|
|
|
|
|
|
Merck Statement on GARDASIL® |
|
|
|
|
|
|
|
|
|
|
9/12/11 |
Bruker Announces Agreement to Acquire CETR |
|
|
|
|
|
Genentech Submits New Drug Application to FDA for Vismodegib for Rare
Form of Advanced Skin Cancer |
|
|
|
|
9/08/11 |
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals |
|
|
|
|
|
Nektar:
Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic
Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer
Symposium |
|
|
|
|
|
Novartis receives EU approval for Votubia®, the first medication to
treat children and adults with SEGA associated with TSC |
|
|
|
|
|
Myriad Genetics Makes Strategic Debt Investment With Exclusive Option to
Acquire Crescendo Bioscience |
|
|
|
|
9/07/11 |
Merck Statement on FOSAMAX® (alendronate
sodium) Product Liability Trial |
|
|
|
|
9/06/11 |
Bruker Introduces amaZon speed(TM) Next-Generation Ion
Trap Mass Spectrometers at HUPO and JAIMA |
|
|
|
|
|
Bruker Introduces PRIME(TM), the first Integrated
Multidimensional Solution for Unraveling the Proteome, at the 10th HUPO
World Congress |
|
|
|
|
|
Biogen Idec Fully Acquires Biogen Dompé Joint Ventures |
|
|
|
|
|
Agilent Technologies Introduces World's Smallest FTIR
Spectrometer
|
|
|
|
|
9/05/11 |
|
|
|
|
|
9/02/11 |
|
|
|
|
|
9/01/11 |
Roche's Tarceva receives European approval for first-line
use in a genetically distinct type of lung cancer |
|
|
|
|
|
|
|
|
|
|
|
Bayer Healthcare to acquire Pathway Medical Technologies |
|
|
|
|
8/30/11 |
Abbott Introduces New ALK Genetic Test for Specific Form
of Non-Small-Cell Lung Cancer |
|
|
|
|
|
Abbott Awards CFCareForward Scholarships to 40
Exceptional Graduate and Undergraduate Students Living with Cystic
Fibrosis |
|
|
|
|
8/29/11 |
FDA requests additional clinical data on Novartis drug ACZ885 for the
treatment of gouty arthritis |
|
|
|
|
|
|
|
|
|
|
8/28/11 |
ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke
or Systemic Embolism with Significantly Less Major Bleeding in Patients
with Atrial Fibrillation in Phase 3 ARISTOTLE Trial |
|
|
|
|
8/26/11 |
Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy
Selection |
|
|
|
|
|
Texas Supreme Court Finds for Merck in VIOXX® Case |
|
|
|
|
8/25/11 |
Linagliptin Receives Approval in
Europe for the Treatment of Type 2 Diabetes |
|
|
|
|
8/24/11 |
Shimadzu Corporation and the University of Tokyo Sign
Joint Research Agreement to Develop Lipidomic Technology for Biomarker
Discovery |
|
|
|
|
|
|
|
8/23/11 |
FDA Grants Fast Track Designation to Bayer’s
Investigational Compound Alpharadin™ for the Treatment of Castration
Resistant Prostate Cancer in Patients with Bone Metastases |
|
|
|
|
|
Agilent Technologies and Chungnam National University
Collaborate to Further Glycomics Research
|
|
|
|
|
|
Thermo Fisher Scientific Completes Acquisition of Phadia |
|
|
|
|
8/22/11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker Launches D8 QUEST and D8 VENTURE Crystallography
Systems with Novel High Intensity X-ray Sources for Structural Biology |
|
|
|
|
|
FDA Clears Abbott’s Genetic FISH Panel for Leukemia
Patient Prognosis |
|
|
|
|
8/19/11 |
|
|
|
|
|
|
Bayer CropScience receives approval for Liberty Link
Soybeans in Argentina |
|
|
|
|
8/17/11 |
Genentech: FDA Approves Zelboraf (Vemurafenib) and
Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a
Deadly Form of Skin Cancer |
|
|
|
|
8/16/11 |
Korean NAQS to Utilize High-Performance Bruker Triple-Quadrupole
GC-MS Systems for Advanced Pesticide Analysis |
|
|
|
|
8/15/11 |
GSK and Impax announce positive topline results of
ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease |
|
|
|
|
|
Gilead's Investigational Antiretroviral Quad Regimen
Meets 48-Week Primary Objective in Pivotal Phase 3 Clinical Study 102 |
|
|
|
|
|
|
|
|
|
|
|
Myriad Announces New $200 Million Share Repurchase
Program |
|
|
|
|
8/10/11 |
Abbott Receives U.S. FDA Approval for RX Herculink Elite®
Renal Stent System for Treatment of Renal Artery Disease |
|
|
|
|
|
Abbott Introduces Vector-borne Pathogen Test to Detect
Microorganisms Carried by Ticks and Other Insects |
|
|
|
|
|
|
|
|
|
|
|
Gilead Sciences Resolves U.S. Food and Drug
Administration Warning Letter Related to San Dimas Manufacturing
Facility |
|
|
|
|
|
U.S. Food and Drug Administration Approves Gilead
Sciences' Complera(TM), a New Complete Once-Daily, Single-Tablet Regimen
for HIV-1 Infection in Treatment-Naïve Adults |
|
|
|
|
|
Lilly:
BYDUREON™ FDA ACTION DATE SET FOR JANUARY 28, 2012
|
|
|
|
|
8/9/11 |
Biogen Idec And Abbott Announce Positive Top-Line Results
From The First Registrational Trial For Daclizumab HYP In
Relapsing-Remitting Multiple Sclerosis |
|
|
|
|
|
|
|
|
|
|
|
Lilly Announces Review of Data on Long-Term Raloxifene
Treatment for Postmenopausal Osteoporosis Published in Current Medical
Research & Opinion |
|
|
|
|
|
Thermo Fisher Scientific Prices Offering of Senior Notes |
|
|
|
|
8/8/11 |
Bayer CropScience receives UK approval for pioneering
seed treatment product:New
potato-enhancing product Emesto™ registered in first market |
|
|
|
|
|
Caliper and Carestream Settle Lawsuits |
|
|
|
|
8/3/11 |
Merck and Serum Institute Announce Collaboration to
Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV)
|
|
|
|
|
|
Gilead Sciences to Purchase Biologics Process Research
and Clinical Manufacturing Facility from Genentech |
|
|
|
|
8/1/11 |
Vermillion Announces Notice of Allowance for Peripheral
Artery Disease (PAD) Patent |
|
|
|
|
7/29/11 |
U.S. Court of Appeals Affirms Validity of Lilly's
Strattera Patent |
|
|
|
|
|
Amgen's Second Quarter 2011 Revenue Increased 4 Percent
to $4.0 Billion |
|
|
|
|
|
BMS:
U.S. Food and Drug Administration Approves Subcutaneous
Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for
Adults with Moderate to Severe Rheumatoid Arthritis |
|
|
|
|
|
Myriad Applauds the Court of Appeals' Decision to Uphold
Gene Patenting |
|
|
|
|
7/28/11 |
Life Technologies Announces Second Quarter 2011 Results
|
|
|
|
|
|
Agilent Technologies' NMR Spectrometer and MRI System
Chosen by National University of Singapore for Environmental Research
|
|
|
|
|
7/27/11 |
Thermo Fisher Scientific Reports Second Quarter 2011
Results |
|
|
|
|
|
Biogen Idec Strengthens MS ActiveSource(R) for People
with Multiple Sclerosis |
|
|
|
|
7/26/11 |
Shimadzu:
National Cancer Center (NCC) and Shimadzu Corporation Reach
Comprehensive Collaborative Research Agreement |
|
|
|
|
|
Thermo Fisher Scientific Introduces Workflows at AACC
2011 to Accelerate Results in the Clinical Laboratory |
|
|
|
|
7/25/11 |
Biogen Idec Receives Conditional Approval in the European
Union for FAMPYRA(R) to Improve Walking in Adults with Multiple
Sclerosis |
|
|
|
|
07/22/11 |
|
|
|
|
|
07/21/11 |
Thermo Fisher Scientific Signs Agreement to Make its
Biomarker Assays Available on Alere Triage Systems |
|
|
|
|
|
Sangamo BioSciences Announces Efficient Generation of
Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology |
|
|
|
|
|
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals |
|
|
|
|
07/20/11 |
|
|
|
|
|
|
Data on Bristol-Myers Squibb’s Investigational Treatment
for Alzheimer’s Disease Demonstrate Potential Therapeutic Window at
Doses Below 100 mg in Phase II Safety and Tolerability Study |
|
|
|
|
07/19/11 |
Thermo Fisher Scientific Receives Two R&D 100 Awards |
|
|
|
|
|
|
|
|
|
|
|
Millennium Submits Supplemental New Drug Application with
FDA for Long-Term Overall Survival Results of VELCADE in Previously
Untreated Multiple Myeloma |
|
|
|
|
07/18/11 |
Thermo Fisher Scientific Acquires TREK Diagnostic Systems |
|
|
|
|
|
Nektar:
NKTR-102 Receives Positive Opinion From EMA COMP for
Orphan Medicinal Product Designation in Ovarian Cancer |
|
|
|
|
|
Merck:
VICTRELIS™ (boceprevir), First-in-Class Oral
Hepatitis C Virus Protease Inhibitor, Approved in the European Union for
Treatment of Chronic Hepatitis C |
|
|
|
|
|
Merck's ISENTRESS® (raltegravir) in
Combination Therapy Demonstrated Efficacy in a Phase II Study Extending
to Nearly Five Years in Previously Untreated Adults with HIV-1
|
|
|
|
|
|
Florbetapir "Imaging to Autopsy" Study Awarded
Alzheimer's Association's 2011 de Leon Prize in Neuroimaging
|
|
|
|
|
|
Lilly:
New Data Showed Minimal Potential for Drug Interaction
Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy
|
|
|
|
|
|
Bruker Brings Exceptional High Performance Single and
Triple Quadrupole Mass Spectrometry to Gas Chromatographers with the
Release of the SCION Series |
|
|
|
|
07/15/11 |
|
|
|
|
|
|
Amgen Resolves G-CSF Patent Litigation With Teva
|
|
|
|
|
|
Amgen:
XGEVA® (Denosumab) Granted Marketing Authorization in the
European Union |
|
|
|
|
07/14/11 |
BMS:
YERVOY™ (ipilimumab) Approved for the Treatment of
Previously-Treated Advanced Melanoma in the EU |
|
|
|
|
|
Life Technologies Develops Potent Drug Delivery
Technology for Therapeutics Market
|
|
|
|
|
|
|
|
|
|
|
|
Genentech: Pertuzumab Combined with Herceptin and
Chemotherapy Significantly Extended the Time People with HER2-Positive
Metastatic Breast Cancer Lived without Their Disease Getting Worse |
|
|
|
|
|
Lilly Diabetes, Disney Online and Disney Publishing
Worldwide Work Together to Bring Dedicated Lifestyle Website and Custom
Publications to Families Affected by Type 1 Diabetes
|
|
|
|
|
07/12/11 |
Life Technologies Introduces First and Only USDA-Approved
Real-Time PCR Test to Detect Swine Influenza Virus
|
|
|
|
|
07/11/11 |
Lilly CEO Says Biopharmaceuticals Should Be Included in
Transatlantic Trade and Economic Discussions |
|
|
|
|
|
Sangamo BioSciences Appoints Dr. Geoffrey Nichol as
Executive Vice President, Research and Development |
|
|
|
|
07/10/11 |
Life Technologies Launches New Distribution Center in
India |
|
|
|
|
07/08/11 |
Novartis:
Phase III trial of Novartis drug Afinitor® met primary
endpoint of reducing SEGA tumor size in patients with tuberous sclerosis |
|
|
|
|
07/07/11 |
Lilly CEO Calls for Improved Dialogue in Germany Between
Industry and the Government and Health Care System |
|
|
|
|
07/06/11 |
Bristol-Myers Squibb and Innate Pharma Announce
Breakthrough Global License Agreement for an Investigational Immuno-Oncology
Biologic |
|
|
|
|
07/05/11 |
Novartis drug Afinitor® met primary endpoint of Phase III
study in women with advanced breast cancer; potential to address
significant unmet need |
|
|
|
|
|
|
|
|
|
|
07/03/11 |
Biogen Idec Researchers Identify Novel Approach for
Promoting Remyelination and Inhibiting Autoimmune Activation as
Potential Therapeutic Option for Treatment of Multiple Sclerosis |
|
|
|
|
07/02/11 |
Bayer CropScience Settles Biotech Rice Litigation |
|
|
|
|
07/01/11 |
Merck Receives Approval to Market GARDASIL®,
ZOLINZA® and CUBICIN® in Japan |
|
|
|
|
|
Novartis receives FDA approval for Arcapta(TM)
Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive
pulmonary disease |
|
|
|
|
06/30/11 |
Lilly Outlines For Investors How Its Innovation-Based
Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming
Patent Expirations |
|
|
|
|
|
Novartis Phase III study shows once-daily NVA237 is
superior to placebo and similar to tiotropium in improving lung function
in COPD |
|
|
|
|
|
Roche’s Avastin receives broader EU label for women with metastatic
breast cancer. Expanded label allows combination
with Xeloda or paclitaxel in first-line setting |
|
|
|
|
06/29/11 |
Genentech Provides Update from FDA Hearing on Avastin for Metastatic
Breast Cancer |
|
|
|
|
06/28/11 |
Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir
sulfate) in sub-Saharan Africa and India |
|
|
|
|
|
GSK welcomes external scientists to diseases of the developing world
research campus |
|
|
|
|
|
Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic
Macular Edema Experienced Significant Improvements in Vision and Fewer
Developed More Advanced Retinopathy |
|
|
|
|
|
Newly Published Study Showed Axiron® (testosterone) Topical Solution
Restored Testosterone Levels to Normal Range in Hypogonadal Men |
|
|
|
|
|
Lilly Announces New Investment to Further Boost Its Biotechnology
Capabilities |
|
|
|
|
|
Agilent Technologies Introduces Sub-Two Micron Reversed-Phase UHPLC
Column, Enabling Fast Higher-Order Protein Characterization |
|
|
|
|
|
Thermo Fisher Scientific Collaboration with U.K. Health Protection
Agency Yields Significant Development in Understanding Toxicity of the
New E. coli Strain |
|
|
|
|
06/27/11 |
Bruker and the Institute of Medical Microbiology at the University of
Zurich Announce a Collaboration for Mass Spectrometry-based Microbial
Identification with Focus on Coryneform Bacteria, Actinomycetes,
Fastidious Gram-negative Rods and Moulds |
|
|
|
|
|
Bruker and Francisco Soria Melguizo S.A. Expand their Exclusive
Agreement for Distribution of the MALDI Biotyper to Cover Spain and
Portugal |
|
|
|
|
|
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to
Prevent or Delay Spread of Prostate Cancer to the Bone |
|
|
|
|
|
Sangamo BioSciences Announces Publication of First Demonstration of In
Vivo Correction of Hemophilia Gene via Systemic Delivery of a ZFP
Therapeutic® |
|
|
|
|
06/24/11 |
Lilly:
New Phase III Data and Pooled Analysis for Linagliptin Show Improved
Blood Sugar Control in Adults With Type 2 Diabetes When Used Alone and
With Metformin |
|
|
|
|
|
Lilly:
Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to
Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2
Diabetes in the U.S. |
|
|
|
|
|
Novartis drug Votubia® recommended by CHMP for approval in the EU for
children and adults with SEGA associated with tuberous sclerosis |
|
|
|
|
|
Roche and Evotec to jointly develop biomarkers in oncology |
|
|
|
|
06/23/11 |
BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from
Pfizer |
|
|
|
|
06/22/11 |
Novartis:
FDA panel endorses efficacy but not safety of Novartis drug ACZ885 for
gouty arthritis; did not support approval in proposed indication |
|
|
|
|
|
Biogen-Idec:
European Commission Approves Inclusion of Anti-JC Virus Antibody Status
as a PML Risk Factor in TYSABRI Labeling |
|
|
|
|
06/21/11 |
|
|
|
|
|
|
Lilly:
The
European Commission has granted marketing authorization to
BYDUREON™ a glucagon-like peptide-1 (GLP-1) receptor agonist, is
the first once-weekly treatment for type 2 diabetes. |
|
|
|
|
|
Depomed Files Patent Infringement Lawsuit against Sun
Pharmaceutical Industries |
|
|
|
|
|
Abbott and Biotest Announce Global Agreement to Develop
and Commercialize Novel Antibody for Autoimmune Diseases |
|
|
|
|
06/20/11 |
|
|
|
|
|
|
Lilly Declares Third-Quarter 2011 Dividend |
|
|
|
|
|
Bruker Expands Infrared Remote Sensing Product Line with
Introduction of Novel Hyperspectral Imaging System HI 90 for up to 1000
Times Faster Measurements |
|
|
|
|
|
Abbott Receives FDA Approval for a New Six-Month
Formulation of Lupron Depot® (leuprolide acetate for depot suspension)
for the Palliative Treatment of Advanced Prostate Cancer |
|
|
|
|
06/19/11 |
Genentech:
Pivotal Study Showed Vismodegib Helped Shrink Tumors or
Heal Lesions in People with Rare Form of Advanced Skin Cancer |
|
|
|
|
06/16/11 |
Abbott:
Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in
Patients with Chronic Kidney Disease and Type 2 Diabetes |
|
|
|
|
|
Novartis begins construction of new state-of-the-art pharmaceutical
manufacturing plant in St. Petersburg, Russia |
|
|
|
|
|
BMS:
FDA Approves NULOJIX® (belatacept)
For Prophylaxis of Organ Rejection in Adult Patients Receiving a Kidney
Transplant in Combination with Basiliximab Induction, Mycophenolate
Mofetil, and Corticosteroids |
|
|
|
|
06/15/11 |
Bristol-Myers Squibb Announces U.S. FDA Approval of NULOJIX® (belatacept) |
|
|
|
|
|
Boehringer Ingelheim and Lilly's New Type 2 Diabetes Treatment Tradjenta™
(Linagliptin) Tablets for Adults Now Available in U.S. Pharmacies |
|
|
|
|
06/13/11 |
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine) |
|
|
|
|
06/10/11 |
Gilead Sciences Receives Subpoena from U.S. Department of Justice |
|
|
|
|
06/07/11 |
BioMarin Initiates Phase 3 Trial for Amifampridine Phosphate for the
Treatment of LEMS |
|
|
|
|
|
Data from Phase 1 Study of NKTR-181 Demonstrate Proof-of-Concept for
Nektar's Novel Opioid Analgesic Candidate |
|
|
|
|
06/06/11 |
Thermo Fisher Scientific Launches New Cutting-Edge Mass
Spectrometry Instruments at ASMS 2011 |
|
|
|
|
|
|
|
|
|
|
|
Myriad's PROLARIS(R) Test Shown to Significantly Predict
Prostate Cancer Outcome From Needle Biopsy Tissue |
|
|
|
|
|
Merck and ARIAD Announce Presentation of Results of Phase
III SUCCEED Trial at American Society of Clinical Oncology Annual
Meeting |
|
|
|
|
|
Life Technologies Develops Fast and Accurate Test to
Detect Europe's Deadly E. coli |
|
|
|
|
|
AB SCIEX Expands Qualification Services and Support for
the Mass Spectrometry Industry’s Widest Range of Front-End Technologies |
|
|
|
|
|
AB SCIEX:
New Technique to Revolutionize Proteomics Mass
Spectrometry |
|
|
|
|
|
AB SCIEX Introduces Breakthrough Performance in
Differential Ion Mobility Spectrometry for Quantitative and Qualitative
Analysis |
|
|
|
|
|
Bruker Announces Release of Breakthrough CaptiveSpray(TM)
Nano/Capillary Electrospray Ion Source for Proteomics at ASMS 2011 |
|
|
|
|
06/05/11 |
Genentech Announces Vemurafenib Improved Survival in
People With Metastatic Melanoma Who Have BRAF V600 Mutations |
|
|
|
|
|
|
|
|
|
|
|
Nektar:
NKTR-102 Shows High Response Rate and Sustained Duration
of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer
Previously Treated with Doxil® |
|
|
|
|
|
NKTR-102 Demonstrates Sustained Clinical Benefit in 46%
of Patients with Metastatic Breast Cancer in Data Presented at 2011
American Society of Clinical Oncology Annual Meeting |
|
|
|
|
|
BMS:
Second Phase 3 Study of YERVOY™ (ipilimumab) in
Metastatic Melanoma Meets Primary Endpoint of Overall Survival |
|
|
|
|
|
Lilly:
New Study Released Today Showed Patients With Deadly Form
of Lung Cancer Lived Longer Without Disease Worsening
|
|
|
|
|
06/04/11 |
Genentech Announces Data to Show Avastin-Based Regimen
Halved the Risk of Disease Getting Worse in Women with Recurrent Ovarian
Cancer |
|
|
|
|
|
|
|
|
|
|
|
Incyte Announces Ruxolitinib (INC424) Shows Significant
Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at
ASCO Annual Meeting |
|
|
|
|
|
|
|
|
|
|
06/02/11 |
Thermo Fisher Scientific Debuts High-Performance Benchtop
Quadrupole-Orbitrap Mass Spectrometer at ASMS 2011 |
|
|
|
|
|
Bruker Drives Ultrahigh-Resolution Qq-TOF Mass
Spectrometry to New Performance Levels with Major Innovations in
maxis(TM) Platform to be Showcased at ASMS 2011 |
|
|
|
|
|
Genentech:
Tarceva Nearly Doubled the Time People with a Genetically
Distinct Type of Lung Cancer Lived without Their Disease Getting Worse
|
|
|
|
|
|
|
|
|
|
|
|
Life Tech:
DNA Sequencing Data Reveals New Hybrid E. coli Strain is
Cause of German Outbreak |
|
|
|
|
|
|
|
|
|
|
06/01/11 |
|
|
|
|
|
|
Myriad Genetics Completes Acquisition of Rules-Based
Medicine |
|
|
|
|
|
Bayer CropScience: a leading partner in the seed
treatment growth market |
|
|
|
|
05/31/11 |
Ion Torrent Ships New RNA Sequencing Application as Fast,
Easy, Affordable Alternative to Microarrays
|
|
|
|
|
|
Bruker Announces Sale of 35 minispec(TM) Benchtop
Time-Domain NMR Analyzers for Oilseed Quality Control to Trakya Birlik,
a Turkish Agricultural Cooperative |
|
|
|
|
05/30/11 |
Shimadzu: Repeatability of 0.5 % in 1 uL injections,
sample injection in as fast as 7 seconds, and the absolute lowest
carryover The Nexera MP Ultra High Performance Liquid Chromatograph
Front End System for LC/MS will be Released. |
|
|
|
|
05/27/11 |
Bruker Launches Novel D8 QUEST and D8 VENTURE High
Performance X-ray Crystallography Systems with Next-Generation Large
Area CMOS Detectors |
|
|
|
|
|
Bayer CropScience successfully pursues imidacloprid
infringers |
|
|
|
|
05/26/11 |
Bruker Expands in China with Opening of Second Major
Applications, Training and Service Center in Shanghai |
|
|
|
|
|
Life Technologies Simplifies, Organizes and Speeds
Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics
Software |
|
|
|
|
05/25/11 |
|
|
|
|
|
|
Lilly Comments on Court Ruling in Amylin Litigation
|
|
|
|
|
|
Vermillion Announces Notice of Allowance for Alzheimer
Patent |
|
|
|
|
|
Abbott Receives CE Mark for its RealTime
Molecular Test for Cytomegalovirus |
|
|
|
|
05/24/11 |
Vermillion:
OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood
Test and Clinical Assessment |
|
|
|
|
|
Bruker Opens New Center of Excellence with Extended
Applications Laboratories and Customer Support Capabilities at the
Biopolis - Singapore's Biomedical Hub |
|
|
|
|
|
Bruker Announces Large Order for EPR Instrumentation in
the UK |
|
|
|
|
|
Abbott Receives U.S. FDA Approval for XIENCE nano™ to
Treat Coronary Artery Disease in Small Vessels |
|
|
|
|
05/20/11 |
|
|
|
|
|
|
Pfizer:
|
|
|
|
|
|
|
|
|
|
|
05/19/11 |
Thermo Fisher Scientific to Acquire Phadia, a Global
Leader in Allergy and Autoimmunity Diagnostics |
|
|
|
|
|
|
|
|
|
|
|
Compugen Discloses Discovery Method for Drug Candidates
That Interfere With Protein Conformations |
|
|
|
|
|
Nexavar in Combination with Chemotherapy Improves
Progression-Free Survival in Patients with Advanced Breast Cancer in
Phase II Study |
|
|
|
|
05/18/11 |
Thermo Fisher Scientific Acquires Leading UK Provider of
Laboratory Specialty Products |
|
|
|
|
|
MetMAb in Combination with Tarceva Doubled the Time
People with Lung Cancer Lived without Their Disease Getting Worse |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Abbott Receives FDA Approval for Molecular Test for
Hepatitis C |
|
|
|
|
05/17/11 |
Thermo Fisher Scientific Completes Acquisition of
Remaining Shares of Dionex Corporation |
|
|
|
|
|
Amgen:
Phase 3 Data Demonstrate XGEVA(TM) (Denosumab) is First
Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men
With Advanced Prostate Cancer |
|
|
|
|
05/16/11 |
Lilly Provides Statement in Response to Amylin Lawsuit
|
|
|
|
|
|
Biogen Idec Receives Approval for FAMPYRA in Australia to
Improve Walking Ability in Adult Patients with MS |
|
|
|
|
05/12/11 |
Bruker Announces $10M in New Orders for Novel Metrology
Tools from Leading Semiconductor Manufacturer |
|
|
|
|
05/11/11 |
|
|
|
|
|
|
|
|
|
|
|
05/10/11 |
Thermo Fisher Scientific Provides Update on Acquisition
of Dionex Corporation |
|
|
|
|
|
Genentech: New Drug Applications Submitted in the United
States and Europe for Vemurafenib in Advanced Skin Cancer
|
|
|
|
|
|
FDA Grants Fast Track Designation to Bayer’s
Investigational Compound Regorafenib for the Treatment of
Gastrointestinal Stromal Tumors |
|
|
|
|
|
Life Technologies Launches 7500 Fast Dx Real-Time PCR
Instrument and 3500 Dx Series Genetic Analyzer in Japan
|
|
|
|
|
05/09/11 |
|
|
|
|
|
|
Geron Statement Regarding European Cancer Vaccine Patents |
|
|
|
|
|
Bruker Announces 15 Tesla Ultra-High Field Preclinical
MRI with CryoProbe(TM) for High Definition Neuroimaging - First Order
Received from Vanderbilt University |
|
|
|
|
|
Biogen Idec and Swedish Orphan Biovitrum Receive Opinion
from EMA on Pediatric Plan for Long-Lasting Hemophilia B Therapy |
|
|
|
|
05/08/11 |
Bruker Announces Integrated Microbiology Workflow For
MALDI Biotyper Microbial Identification and BD Phoenix TM Antibiotic
Susceptibility Testing |
|
|
|
|
05/06/11 |
|
|
|
|
|
|
Millenium:
VELCADE Improved Outcomes In Multiple Myeloma Patients
After Transplant In Nordic Myeloma Study |
|
|
|
|
05/05/11 |
|
|
|
|
|
|
Millennium Pharmaceuticals and Sunesis Pharmaceuticals
Announce Collaboration for Kinase Inhibitors in Oncology |
|
|
|
|
|
Millennium Leadership In Proteasome Inhibition
Highlighted In Relapsed/Refractory Multiple Myeloma At IMW Meeting |
|
|
|
|
|
Gilead Extends Its Funding Support for the Gilead
Sciences Research Centre at the Institute of Organic Chemistry and
Biochemistry in Prague |
|
|
|
|
05/04/11 |
|
|
|
|
|
|
Geron Announces $25 Million in Funding from California
Institute of Regenerative Medicine |
|
|
|
|
05/02/11 |
Bruker Announces Dimension
FastScan, the World's Fastest High-Resolution Atomic Force Microscope |
|
|
|
|
|
Merck’s Investigational Prostaglandin Analogue Ophthalmic
Medication Tafluprost Meets Primary Endpoint in Phase III Study |
|
|
|
|
|
Video: FDA Approves Tradjenta™ (linagliptin) Tablets for
the Treatment of Type 2 Diabetes
|
|
|
|
|
04/29/11 |
Abbott Receives U.S. FDA Approval
for AndroGel® 1.62% to Treat Men with Low Testosterone |
|
|
|
|
04/28/11 |
|
|
|
|
|
|
|
|
|
|
|
|
Myriad Genetics Inc. (Nasdaq:MYGN)
today announced that it has entered into a definitive merger agreement
to acquire privately-held Rules-Based Medicine (RBM) of Austin, Texas
for $80 million in cash. |
|
|
|
|
|
|
|
|
|
|
04/27/11 |
|
|
|
VICTRELIS™ (boceprevir) Unanimously Recommended for Approval
by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1
Infection |
|
|
|
|
|
Merck Announces New $5 Billion Share Repurchase Program |
|
|
|
|
|
U.S. District Court Order Maintains Patent Exclusivity for Lilly's
Cymbalta |
|
|
|
|
|
Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Second
Phase 3 Study in Central Retinal Vein Occlusion |
|
|
|
|
|
Bayer CropScience at the International Seed Federation Congress 2011 in
Belfast:
Sustainable solutions for higher yields and more added value » more
|
|
|
|
|
04/26/11 |
Millennium Submits Two Supplemental NDAs To FDA For VELCADE |
|
|
|
|
|
Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's
Disease |
|
|
|
|
|
Bruker Corporation to Release First Quarter Financial Results on April
28, 2011 |
|
|
|
|
04/25/11 |
Rwanda, Merck and QIAGEN Launch Africa's First Comprehensive Cervical
Cancer Prevention Program Incorporating Both HPV Vaccination and HPV
Testing |
|
|
|
|
04/21/11 |
|
| |
|
| |
FDA Grants Orphan Drug Designation for Nektar's
Investigational Drug, NKTR-102, for Treatment of Women with Ovarian
Cancer |
| |
|
| |
Merck and Sanofi Pasteur Initiate Phase III Study in the
United States of Pediatric Combination Vaccine to Help Prevent Six
Infectious Diseases |
| |
|
|
04/20/11 |
FDA Approves Roche’s HPV Test for Identifying Women at
Highest Risk for Cervical Cancer |
| |
|
| |
|
| |
|
| |
Gilead and MicroDose Therapeutx Announce License and
Collaboration Agreement to Develop MDT-637 for Treatment of Respiratory
Syncytial Virus |
| |
|
| |
Amgen's First Quarter 2011 Revenue Increased 3 Percent to
$3.7 Billion |
| |
|
| |
Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent
Ongoing Earnings-Per-Share Growth in First Quarter |
| |
|
|
04/19/11 |
Sangamo BioSciences Announces First
Quarter 2011 Conference Call and Webcast |
| |
|
| |
Novartis generates strong sales growth of 14% in constant
currencies in first quarter, operating income impacted by 2010 sales
from A(H1N1) pandemic flu vaccines |
| |
|
| |
Genentech: FDA Approves Rituxan
Plus a Steroid for Use in Severe Forms of Vasculitis |
| |
|
| |
Biogen_Idec
FDA Approves Rituxan Plus a Steroid for Use in Severe
Forms of Vasculitis |
| |
|
| |
Biogen Idec Receives Positive Opinion from the CHMP and
Authorisation from Health Canada on AVONEX PEN |
| |
|
|
04/18/11 |
FDA approves Actemra for the treatment of Systemic
Juvenile Idiopathic Arthritis (SJIA) |
| |
|
| |
GSK welcomes key agreement to support global preparedness
against pandemic influenza |
| |
|
| |
Lilly Declares Second-Quarter 2011 Dividend
|
| |
|
|
04/15/11 |
Lilly Receives Complete Response Letter From FDA for Liprotamase for the
Treatment of Exocrine Pancreatic Insufficiency |
| |
|
| |
Genentech: FDA Approves ACTEMRA® (tocilizumab) for the Treatment of
Systemic Juvenile Idiopathic Arthritis (SJIA) |
| |
|
| |
Regulatory Update: GlaxoSmithKline submits additional information for
candidate meningococcal and Hib combination vaccine |
| |
|
| |
Merck Commences Tender
Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc.
|
| |
|
| |
Roche gains positive CHMP opinion for the combination of Avastin with
Xeloda as a first-line treatment for metastatic breast cancer in Europe |
| |
|
| |
Pfizer Announces Top-Line Results Of Third Phase 3 Clinical Trial Of
Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis |
| |
|
| |
AstraZeneca Initiates Phase III Clinical Programme
Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation |
| |
|
| |
Merck Commences Tender Offer for all Outstanding Shares
of Inspire Pharmaceuticals, Inc. |
| |
|
|
|
|
|
